Study guide

4.2 Conflicts of Interest

Certified Clinical Research Coordinator CCRC

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Scientific Concepts and Research Design

1.1 Protocol Elements 1.2 Study Design and Objectives 1.3 Study Endpoints and Biostatistics

2 Chapter 2: Ethical Principles and Guidelines

2.1 Ethical Principles (Declaration of Helsinki, Belmont Report) 2.2 Informed Consent Process and Documentation 2.3 Vulnerable Populations and Assent

3 Chapter 3: IRB/IEC Oversight and Participant Safety

3.1 IRB/IEC Functions and Oversight 3.2 Adverse Event Classification and Reporting 3.3 Safety Monitoring and Safety Reporting

4 Chapter 4: Participant Rights and Ethics

4.1 Participant Rights and Confidentiality (HIPAA/GDPR) 4.2 Conflicts of Interest 4.3 Ethical Scenarios in Clinical Trials

5 Chapter 5: Product Development and Regulatory Framework

5.1 Drug and Device Development Phases 5.2 U.S. and International Regulatory Frameworks 5.3 Investigational Product Investigator's Brochure (IB)

6 Chapter 6: Investigational Product Accountability

6.1 Investigational Product Labeling and Storage 6.2 Investigational Product Receipt, Dispensing, and Accountability 6.3 Investigational Product Return and Destruction

7 Chapter 7: Regulatory Submissions and Actions

7.1 Regulatory Submissions (IND, NDA, IDE, PMA) 7.2 Regulatory Actions and Compliance 7.3 Pharmacokinetics and Pharmacodynamics in Product Development

8 Chapter 8: Clinical Trial Operations and GCP Principles

8.1 Introduction to ICH E6 GCP Principles (including R3 updates) 8.2 Investigator Responsibilities under GCP 8.3 Sponsor Responsibilities and Oversight

9 Chapter 9: Essential Documents and Site Qualification

9.1 Essential Documents (Pre-study, During, Post-study) 9.2 Site Selection and Qualification 9.3 Quality Management and Standard Operating Procedures (SOPs)

10 Chapter 10: Protocol Deviations and Amendments

10.1 Protocol Adherence and Compliance 10.2 Protocol Deviations and Violations 10.3 Protocol Amendments and Version Control

11 Chapter 11: Monitoring Visits and Audits

11.1 Monitoring Preparation and Visit Types 11.2 Monitoring Visits (SIV, IMV, COV) 11.3 Regulatory Inspections and Site Audits

12 Chapter 12: Study and Site Management - Startup

12.1 Site Startup Operations 12.2 Site Budget and Contract Management 12.3 Site Staffing, Training, and Documentation

13 Chapter 13: Enrollment and Recruitment

13.1 Enrollment Management and Strategies 13.2 Participant Recruitment and Retention 13.3 Participant Compensation and Ethics

14 Chapter 14: Daily Trial Coordination

14.1 Visit Scheduling and Logistics 14.2 Equipment Maintenance and Calibration 14.3 Specimen Handling and Shipping (IATA/dangerous goods)

15 Chapter 15: Quality Improvement and Site Closeout

15.1 Participant Safety Management 15.2 Quality Improvement and Site Audits Preparation 15.3 Study and Site Closeout Procedures

16 Chapter 16: Source Documentation and Case Report Forms

16.1 Source Documentation Standards (ALCOA-C) 16.2 Case Report Forms and eCRF Completion 16.3 Electronic Data Capture (EDC) Systems

17 Chapter 17: Data Management and Queries

17.1 Data Management Processes 17.2 Data Queries and Discrepancy Resolution 17.3 Data Correction and Audit Trails

18 Chapter 18: Data Privacy and Records Retention

18.1 Data Privacy and Confidentiality 18.2 Records Retention and Archiving 18.3 Compliance in Clinical Trial Informatics

4.2 Conflicts of Interest

Key Takeaways Explain This Topic AI

A Conflict of Interest (COI) occurs when personal interests could compromise professional judgment in research.

Financial COIs are the most common and strictly regulated, involving stock ownership, consulting fees, or patents.

Non-financial COIs include academic advancement, personal relationships, or institutional pressures.

Management of COIs relies on disclosure, transparency, and sometimes removing the conflicted individual from certain tasks.

Last updated: October 2026

Conflicts of Interest in Clinical Research

A Conflict of Interest (COI) exists when an individual's personal interests (financial or otherwise) have the potential to compromise or bias their professional judgment, objectivity, or obligations in conducting research. In clinical trials, COIs are critical because they can threaten the safety of human subjects and the scientific integrity of the data.

It is important to understand that having a COI is not inherently unethical or illegal. The ethical violation occurs when a conflict is hidden, ignored, or improperly managed. The research enterprise relies heavily on collaboration between academia and industry, making some level of overlapping interests inevitable. The goal is transparency and management, not necessarily elimination.

Types of Conflicts of Interest

Conflicts of interest generally fall into two broad categories: financial and non-financial.

1. Financial Conflicts of Interest (FCOI)

Financial conflicts are the most common and the most heavily regulated. They occur when a researcher has a financial stake that could be affected by the outcome of the research. Examples include:

Equity/Stock Ownership: An investigator owns significant stock in the pharmaceutical company sponsoring the trial.

Consulting Fees: An investigator receives substantial compensation for advising the sponsor on other projects.

Intellectual Property: An investigator holds a patent on the drug or device being tested.

Honoraria and Speaking Fees: The sponsor pays the investigator to speak at conferences.

Significant Financial Interest (SFI)

Regulatory bodies define what constitutes a "Significant Financial Interest." For instance, under Public Health Service (PHS) regulations (which apply to NIH-funded research), an SFI typically includes remuneration or equity interest exceeding $5,000, or any equity interest in a non-publicly traded entity.

2. Non-Financial Conflicts of Interest

Non-financial conflicts can be harder to identify but are equally capable of causing bias. Examples include:

Academic Advancement: The pressure to publish positive results to secure tenure or promotion.

Personal Relationships: Hiring a family member to work on the study team, or enrolling a close friend as a participant.

Institutional Conflicts: When the research institution itself holds a patent on the investigational product or has equity in the sponsoring company.

Regulatory Requirements and Disclosure

The management of COIs relies heavily on disclosure. Investigators and key study personnel are required to disclose their financial interests to their institution and, often, to the sponsor and the FDA.

FDA Form 3455

The FDA requires sponsors to submit financial disclosure information for clinical investigators. This is done using FDA Form 3455 (Disclosure: Financial Interests and Arrangements of Clinical Investigators). Investigators must disclose:

Compensation made to the investigator where the value could be influenced by the outcome of the study.

Significant equity interest in the sponsor.

Proprietary interest in the tested product (patents, trademarks).

Significant payments of other sorts (SPOs) from the sponsor, such as grants or equipment.

If an investigator has no such interests, FDA Form 3454 (Certification: Financial Interests and Arrangements of Clinical Investigators) is used instead.

Institutional Policies

Most research institutions have their own COI policies, often managed by a dedicated Conflict of Interest Committee (COIC). Researchers must complete annual disclosure forms and update them whenever their financial situation changes.